Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Invested Capital (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Invested Capital for 4 consecutive years, with $296.9 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 166.25% to $296.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $296.9 million through Dec 2025, up 166.25% year-over-year, with the annual reading at $296.9 million for FY2025, 166.25% up from the prior year.
  • Invested Capital hit $296.9 million in Q4 2025 for Taysha Gene Therapies, up from $219.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $296.9 million in Q4 2025 to a low of -$37.1 million in Q2 2023.
  • Historically, Invested Capital has averaged $80.7 million across 4 years, with a median of $54.5 million in 2024.
  • Biggest YoY gain for Invested Capital was 7796.42% in 2023; the steepest drop was 214.17% in 2023.
  • Year by year, Invested Capital stood at $949000.0 in 2022, then surged by 7796.42% to $74.9 million in 2023, then skyrocketed by 48.83% to $111.5 million in 2024, then soared by 166.25% to $296.9 million in 2025.
  • Business Quant data shows Invested Capital for TSHA at $296.9 million in Q4 2025, $219.0 million in Q3 2025, and $248.7 million in Q2 2025.